HC Wainwright & Co. Reiterates Buy on AngioDynamics, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for AngioDynamics (NASDAQ:ANGO) and maintained a price target of $14.
September 20, 2024 | 10:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for AngioDynamics and maintained a $14 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $14 price target by HC Wainwright & Co. suggests positive sentiment and confidence in AngioDynamics' future performance. This could lead to a short-term positive impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100